Table 2.
Biomarker evaluations with classical chemotherapeutic agents in the treatment of triple-negative breast cancer in the neoadjuvant setting.
| Chemotherapy regimen | Potential biomarker(s) | pCR rate | Method of testing | Type of study |
|---|---|---|---|---|
| Docetaxel and epirubicin [Li et al. 2011] |
Basal-like markers negative Nm23-H1 positive |
72.7% 53.8% |
IHC | Prospective |
| Cisplatin [Byrski et al. 2010] |
BRCA1 mutation | 83% | PCR | Retrospective |
| Docetaxel and doxorubicin [Keam et al. 2011] |
High Ki-67 | 18.2% | IHC | Retrospective |
| Anthracycline-based therapy [Bidard et al. 2008] |
p53 positive | 22.5%* | IHC | Retrospective |
| TAC [Von Minckwitz et al. 2011] |
High cytoplasmic PARP | 41% | IHC | Retrospective |
| Anthracycline and taxane combinations [Darb-Esfahani et al. 2012] |
High TMSB15A expression | 47.2% and 36.8%** | qRT-PCR | Retrospective |
| Various regimens [Dennison et al. 2013] |
High LDHB expression | 45.5% and 36.6%** | Microarray | Retrospective |
| Anthracycline or taxane-based therapy [Ono et al. 2012] |
High tumor-infiltrating lymphocytes | 37% | Histopathologic evaluation | Retrospective |
*
Not statistically significant increase.
**
Two datasets evaluated.
IHC, immunohistochemistry; PARP, poly ADP ribose polymerase; pCR, pathologic complete response; PCR, polymerase chain reaction; qRT-PCR, quantitative real-time polymerase chain reaction; TAC, docetaxel, doxorubicin, and cyclophosphamide.